Lymphoma 2006: Classification and treatment

ONCOLOGY

Volumn 20, Issue 3, 2006, Pages 231-239

  Armitage, James O ^a   Bierman, Philip J ^a   Bociek, R Gregory ^a   Vose, Julie M ^a   Neumann, M ^a   Harris, Mildred E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; ANTINEOPLASTIC AGENT;

ASPIRATION BIOPSY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER STAGING; CANCER THERAPY; DIAGNOSTIC PROCEDURE; GENE TRANSLOCATION; GENETIC ANALYSIS; HUMAN; IMMUNOPHENOTYPING; NONHODGKIN LYMPHOMA; PROGNOSIS; REVIEW; TREATMENT OUTCOME; CLASSIFICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 33745626500     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 49:2112-2135, 1982.
2. Hicks EB, Rappaport H, Winter WJ: Follicular lymphoma: A re-evaluation of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. Cancer 9:792-821, 1956.
3. Lukes RJ, Collins RD: Immunologic characterization of human malignant lymphomas. Cancer 34(4 suppl): 1488-503, 1974.
4. Lennert K, Stein H, Kaiserling E: Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 31(suppl 2):29-43, 1975.
5. Kim H, Zelman RJ, Fox MA, et al: Pathology Panel for Lymphoma Clinical Studies: A comprehensive analysis of cases accumulated since its inception. J Natl Cancer Inst 68:43-67, 1982.
6. Whitcomb CC, Crissman JD, Flint A, et al: Reproducibility in morphologic classification of non-Hodgkin's lymphomas using the Lukes-Collins system. The Southeastern Cancer Study Group experience. Am J Clin Pathol 82:383-388, 1984.
7. Classification of non-Hodgkin's lymphomas. Reproducibility of major classification systems. NCI non-Hodgkin's Classification Project Writing Committee. Cancer 55:91-95, 1985.
8. Dick F, VanLier S, Banks P, et al: Use of the working formulation for non-Hodgkin's lymphoma in epidemiologic studies: Agreement between reported diagnoses and a panel of experienced pathologists. J Natl Cancer Inst 78:1137-1144, 1987.
9. Carbone PP, Kaplan HS, Musshoff K, et al: Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 31:1860-1861, 1971.
10. Shipp MA, Harrington DP, Klatt MM, et al: Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104:757-765, 1986.
11. Jagannath S, Velasquez WS, Tucker SL, et al: Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 4:859-865, 1986.
12. Harris NL, Jaffe ES, Stein H, et al: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group [see comments]. Blood 84:1361-1392, 1994.
13. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 89:3909-3918, 1997.
14. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, in Jaffe E, Harris N, Stein H, et al (eds): World Health Organization Classification of Tumors. Lyon, IARC Press, 2001.
15. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.
16. Rosenwald A, Wright G, Chan WC, et al: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.
17. Savage KJ, Monti S, Kutok JL, et al: The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 102:3871-3879, 2003.
18. Dave SS, Fu K, Wright G, et al: Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens (abstract 415). Blood 106:125a, 2005.
19. Dave SS, Wright G, Tan B, et al: Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159-2169, 2004.
20. Hehn ST, Grogan TM, Miller TP: Utility of fine-needle aspiration as a diagnostic technique in lymphoma. J Clin Oncol 22:3046-3052, 2004.
21. Landgren O, Porwit MacDonald A, Tani E, et al: A prospective comparison of fine-needle aspiration cytology and histopathology in the diagnosis and classification of lymphomas. Hematol J 5:69-76, 2004.
22. Gascoyne RD, Aoun P, Wu D, et al: Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93:3913-3921, 1999.
23. AJCC Cancer Staging Manual, 6th ed. New York, Springer, 2002.
24. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993.
25. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma International Prognostic Index. Blood 104:1258-1265, 2004.
26. Gallamini A, Stelitano C, Calvi R, et al: Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 103:2474-2479, 2004.
27. Kersten MJ, Jong DdD, Raemaekers JM, et al: Beyond the International Prognostic Index: New prognostic factors in follicular lymphoma and diffuse large-cell lymphoma: A meeting report of the Second International Lunenburg Lymphoma Workshop. Hematol J 5:202-208, 2004.
28. Sehn LH, Chhanabhai M, Fitzgerald C, et al: Revised International Prognostic Index (R-IPI) is a better predictor ofoutcome than the standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP) (abstract 492). Blood 106:147a, 2005.
29. Tsimberidou AM, Sarris AH, Medeiros LJ, et al: Hodgkin's disease in patients infected with human immunodeficiency virus: Frequency, presentation and clinical outcome. Leuk Lymphoma 41:535-544, 2001.
30. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphomas. From the members of the International Harmonization Project (IHP) of the competence network malignant lymphoma (abstract 18). Blood 106:10a, 2005.
31. Abrey LE, Batchelor TT, Ferreri AJ, et al: Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 23:5034-5043, 2005.
32. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma [see comments]. N Engl J Med 328:1002-1006, 1993.
33. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002.
34. Coiffier B, Reyes F: Best treatment of aggressive non-Hodgkin's lymphoma: A French perspective. Oncology 19(suppl 1):7-15, 2005.
35. Pfreundschuh M, Trumper L, Kloess M, et al: Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-641, 2004.
36. Pfreundschuch M, Kloess M, Schmits R, et al: Six, not eight cycles of Bi-weekly CHOP with rituximab (R-CHOP-14) is the preferred treatment for elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the RICOVER-60 trial of the German high-grade non-Hodgkin lymphoma study group (DSHNHL) (abstract 13). Blood 106:9a, 2005.
37. Pfreundschuch M, Truemper LGD, Gill D, et al: First analysis of the completed Mabthera International (MInT) Trial in young patients with low-risk diffuse large B-cell lymphoma (DLBCL): Addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI=O and no bulky disease (abstract 157). Blood 104:48a, 2004.
38. Sehn LH, Donaldson J, Chhanabhai M, et al: Introduction of combined CHOP-rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma (DLBC) in British Columbia (BC) (abstract 88). Blood 102:29a, 2003.
39. Miller TP, Dahlberg S, Cassady JR, et al: Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma [see comments]. N Engl J Med 339:21-26, 1998.
40. Reyes F, Lepage E, Ganem G, et al: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352:1197-1205, 2005.
41. Fillet G, Bonnet C, Mounier N, et al: No role for chemoradiotherapy when compared with chemotherapy alone in elderly patients with localized low risk aggressive lymhoma: final results of the LNH93-4 GELA study (abstract 15). Blood 106:9a, 2005.
42. Miller TP, Unger JM, Spier CM, et al: Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014) (abstract 158). Blood 104:48a, 2004.
43. Haioun C, Lepage E, Gisselbrecht C, et al: Survival benefit of high-dose therapy in poor-risk aggressive non- Hodgkin's lymphoma: Final analysis of the prospective LNH87-2 protocol - a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 18:3025-3030, 2000.
44. Portlock CS, Rosenberg SA: No initial therapy for stage III and IV non-Hodgkin's lymphomas of favorable histologic types. Ann Intern Med 90:10-13, 1979.
45. Hainsworth JD, Litchy S, Burris HA 3rd, et al: Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol 20:4261-4267, 2002.
46. Ghielmini M, Schmitz SF, Cogliatti SB, et al: Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 103:4416-4423, 2004.
47. Kaminski MS, Zasadny KR, Francis IR, et al: Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 329:459-465, 1993.
48. Hochster HS, Weller E, Gascoyne RD, et al: Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): Results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B (abstract 349). Blood 106:106a, 2005.
49. Solal-Celigny P, Imrie K, Belch A, Robinson KS, et al: Mabthera (rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin's lymphoma (NHL): Confirmed efficacy with longer follow-up (abstract #350). Blood 106:106a, 2005.
50. Schulz H, Skoetz N, Bohlius J, et al: Does combined immunochemotherapy with the monoclonal antibody rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin's lymphoma? Preliminary results of a comprehensive meta-analysis (abstract 351). Blood 106:106a, 2005.
51. Davies AJ, Apostolidis J, Micallef IN, et al: Long-term follow up of patients with follicular lymphoma (FL) receiving high dose therapy (HDT) with autologous haematopoietic progenitor cell support at St. Bartholomew's Hospital (SBH) (abstract 6568). J Clin Oncol 23(16S):577s, 2005.
52. Lenz G, Dreyling M, Schiegnitz E, et al: Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: Results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 104:2667-2674, 2004.
53. van Besien K, Loberiza FR Jr, Bajorunaite R, et al: Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 102:3521-3529, 2003.
54. Escalon MP, Champlin RE, Saliba RM, et al: Nonmyeloablative allogeneic hematopoietic transplantation: A promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 22:2419-2423, 2004.
55. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803-3809, 1998.
56. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005.
57. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005.
58. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005.
59. Magrath I, Adde M, Shad A, et al: Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14:925-934, 1996.
60. Thomas D, Cortes J, Faderl S, et al: Outcome with the Hyper-CVAD and rituximab regimen in Burkitt (BL) and Burkitt-like (BLL) leukemia/lymphoma (abstract 3297). Blood 104:901a, 2004.
61. Isaacson P, Wright DH: Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 52:1410-1416, 1983.
62. Wotherspoon AC, Doglioni C, Diss TC, et al: Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori [see comments]. Lancet 342:575-577, 1993.
63. Thiede C, Wundisch T, Alpen B, et al: Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 19:1600-1609, 2001.
64. Gisselbrecht C, Gaulard P, Lepage E, et al: Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 92:76-82, 1998.
65. Vose J: International peripheral T-cell lymphoma (PTCL) clinical and pathologic review project: poor outcome by prognostic indices an lack of eficacy with anthracyclines (abstract 811). Blood 106:239a, 2005.
66. Ascani S, Zinzani PL, Gherlinzoni F, et al: Peripheral T-cell lymphomas. Clinico-pathologic study of 168 cases diagnosed according to the R.E.A.L. Classification. Ann Oncol 8:583-592, 1997.
67. Savage KJ, Chhanabhai M, Gascoyne RD, et al: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467-1475, 2004.